Core Insights - Kuros Biosciences will present at the Piper Sandler 37th Annual Healthcare Conference, showcasing its innovative biologic technologies and commercial momentum [1][2] - The presentation will focus on clinical advancements in the MagnetOs portfolio, expansion into new indications, and the company's path to sustainable profitability [2] Company Overview - Kuros Biosciences is dedicated to discovering, developing, and delivering innovative biologic technologies, with operations in the United States, Switzerland, and the Netherlands [7] - The company's first commercial product, MagnetOs, is an advanced bone graft used globally across five continents [7] Product Details - MagnetOs has demonstrated a fusion rate of 79% in a Level I clinical study, nearly double that of autograft at 47% [5] - The product utilizes NeedleGrip technology to stimulate bone growth without added cells or growth factors, and is FDA cleared for use throughout the spine [5] Presentation Details - The presentation will be led by Chris Fair, CEO of Kuros Biosciences, on December 3, 2025, at The Lotte New York Palace in New York City [3] - A live webcast of the presentation will be available for 30 days post-event [3]